ANL 28.52 Increased By ▲ 0.14 (0.49%)
ASC 16.71 Increased By ▲ 0.02 (0.12%)
ASL 23.75 Decreased By ▼ -0.11 (-0.46%)
AVN 94.24 Decreased By ▼ -0.65 (-0.69%)
BOP 9.47 Decreased By ▼ -0.02 (-0.21%)
BYCO 9.57 Decreased By ▼ -0.05 (-0.52%)
DGKC 110.51 Increased By ▲ 0.02 (0.02%)
EPCL 47.50 Decreased By ▼ -0.02 (-0.04%)
FCCL 21.15 Decreased By ▼ -0.15 (-0.7%)
FFBL 27.96 Increased By ▲ 0.08 (0.29%)
FFL 19.27 Decreased By ▼ -0.08 (-0.41%)
HASCOL 14.31 Decreased By ▼ -0.01 (-0.07%)
HUBC 86.00 Decreased By ▼ -0.14 (-0.16%)
HUMNL 7.26 Decreased By ▼ -0.03 (-0.41%)
JSCL 31.45 Decreased By ▼ -0.15 (-0.47%)
KAPCO 40.76 Decreased By ▼ -0.07 (-0.17%)
KEL 4.10 Decreased By ▼ -0.01 (-0.24%)
LOTCHEM 16.19 Increased By ▲ 0.03 (0.19%)
MLCF 43.05 Decreased By ▼ -0.16 (-0.37%)
PAEL 39.85 Increased By ▲ 0.01 (0.03%)
PIBTL 12.90 Decreased By ▼ -0.09 (-0.69%)
POWER 11.40 Decreased By ▼ -0.01 (-0.09%)
PPL 93.29 Decreased By ▼ -0.39 (-0.42%)
PRL 23.80 Decreased By ▼ -0.08 (-0.34%)
PTC 9.30 Decreased By ▼ -0.02 (-0.21%)
SILK 1.21 Decreased By ▼ -0.01 (-0.82%)
SNGP 44.34 Decreased By ▼ -0.14 (-0.31%)
TRG 108.48 Decreased By ▼ -1.23 (-1.12%)
UNITY 33.15 Increased By ▲ 0.04 (0.12%)
WTL 1.12 No Change ▼ 0.00 (0%)
BR100 4,856 Decreased By ▼ -9.94 (-0.2%)
BR30 24,724 Decreased By ▼ -96.85 (-0.39%)
KSE100 45,868 Decreased By ▼ -116.42 (-0.25%)
KSE30 19,061 Decreased By ▼ -87.18 (-0.46%)
World

Russia's COVID-19 cases soar; second vaccine due in 2021

  • The vaccine's effectiveness can only be assessed when preliminary or final results of the post-registration trials are released, Vector said.
20 Nov 2020

MOSCOW: The developers of Russia's second vaccine against COVID-19 on Friday said mass production would begin in 2021, as Russia reported a record daily increase in coronavirus infections.

A recent surge in cases has taken Russia past the 2 million threshold, behind only the United States, India, Brazil and France in total infections.

Authorities have resisted imposing lockdowns across the country as they did earlier this year, however, preferring targeted, regional measures.

Russia last week said its first vaccine against COVID-19, Sputnik V, was 92% effective, according to interim trial results. Around 500,000 doses are due to be produced in November.

Post-registration trials for the second vaccine, EpiVacCorona, being developed by Siberia's Vector institute, are underway.

"Mass production will start in 2021 with the involvement of industrial partners," the institute was cited as saying by news agencies. "To date, 15,000 doses of the vaccine have been issued. By the end of the year 50,000 doses will be released."

Vector's vaccine centre said all volunteers injected with EpiVacCorona had developed antibodies against COVID-19, the Interfax news agency reported without specifying the number of people involved.

The vaccine's effectiveness can only be assessed when preliminary or final results of the post-registration trials are released, Vector said.

Antonina Ploskireva, an epidemiologist at consumer health watchdog Rospotrebnadzor, on Friday urged people to continue observing strict rules for wearing masks and gloves and underlined the importance of social distancing.

"There is a specific trend towards the start of stabilisation as a whole in Russia; however, it is premature to speak about this phase," she was cited as saying by RIA.

Authorities reported 24,318 new coronavirus infections on Friday, including 6,902 in Moscow, bringing the national tally to 2,039,926.

Russia also reported 461 coronavirus-related deaths in the last 24 hours, taking the official death toll to 35,311.